Tough choices: tenofovir, tenders and treatment

Hdl Handle:
http://hdl.handle.net/10144/29474
Title:
Tough choices: tenofovir, tenders and treatment
Authors:
Ford, N; Gray, A; Venter, F
Journal:
Southern African Journal of HIV Medicine
Abstract:
Scaling up antiretroviral therapy (ART) in developing countries would not have been possible without market competition, which has driven down the price of standard first-line ARV drugs from more than US$12,000 per person per year in 2000 to US$99 today. However, access to new, second-line ARVs remains largely restricted to originator (patented) drugs. This causes significant challenges in countries where access to newer drugs is becoming inceasingly important as programmes mature and face challenges related to drug toxicity and resistance. Toxicity, in particular, has emerged as a major reason for individual drug switches and regimen changes, and is strongly implicated in decreasing adherence.
Publisher:
South African Medical Association
Issue Date:
4-Jun-2008
URI:
http://hdl.handle.net/10144/29474
Submitted date:
2008
Language:
en
Appears in Collections:
Health Politics; HIV/AIDS

Full metadata record

DC FieldValue Language
dc.contributor.authorFord, N-
dc.contributor.authorGray, A-
dc.contributor.authorVenter, F-
dc.date.accessioned2008-06-04T11:19:39Z-
dc.date.available2008-06-04T11:19:39Z-
dc.date.issued2008-06-04-
dc.date.submitted2008-
dc.identifier.urihttp://hdl.handle.net/10144/29474-
dc.description.abstractScaling up antiretroviral therapy (ART) in developing countries would not have been possible without market competition, which has driven down the price of standard first-line ARV drugs from more than US$12,000 per person per year in 2000 to US$99 today. However, access to new, second-line ARVs remains largely restricted to originator (patented) drugs. This causes significant challenges in countries where access to newer drugs is becoming inceasingly important as programmes mature and face challenges related to drug toxicity and resistance. Toxicity, in particular, has emerged as a major reason for individual drug switches and regimen changes, and is strongly implicated in decreasing adherence.en
dc.language.isoenen
dc.publisherSouth African Medical Associationen
dc.rightsArchived with thanks to the Southern African Journal of HIV Medicineen
dc.subjectTreatmenten
dc.subjectHIVen
dc.subjectTenofoviren
dc.subjectSecond-lineen
dc.titleTough choices: tenofovir, tenders and treatmenten
dc.identifier.journalSouthern African Journal of HIV Medicineen
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.